Acute Myeloid Leukemia (AML) — Deal Benchmarks & Valuation
Market Analysis
Acute Myeloid Leukemia (AML) is one of the most actively transacted indications in oncology licensing. Phase 2 deals for acute myeloid leukemia (aml) carry a median total deal value of $2.2B, with upfront payments ranging from $189M to $479M. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones.
Milestone structures for acute myeloid leukemia (aml) deals allocate $453M to development milestones, $725M to regulatory milestones, and $635M to commercial milestones. Royalty rates range from 12.8% to 20.9% at the base tier, with tiered escalation reaching 16.8%-24.9% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for acute myeloid leukemia (aml) licensing?
What royalty rates are standard for acute myeloid leukemia (aml) deals?
How are acute myeloid leukemia (aml) deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.